Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8 T cells [dataset 2]
Single-cell RNA-seq · human · 40 samples
- What it is
- Single-cell RNA-seqGene activity measured in thousands of individual cells, so cell types can be told apart. Read from the summary: GEO's own type field only says 'expression profiling by sequencing', so confirm it in the paper.
- Organism
- Homo sapiens (human)
- Samples
- 40 samples: 8 conditions, mostly with about 5 replicates eachGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8(+) T cellsCancer cell · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE272734_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Single-cell studies usually ship their counts as 10x files (matrix.mtx, barcodes.tsv, features.tsv), an .h5 file, or an .rds / .h5ad object that Seurat or Scanpy can open. Look for those among the supplementary files.
Also filed as BioProject PRJNA1138630 and SRA study SRP521306. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 40 samples.
How we read this: 8 replicated groups read from 40 sample titles; they account for 40 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8409822 GEX-13-689-wk0 GEX-13-689-wk
- GSM8409823 GEX-13-689-wk3 GEX-13-689-wk
- GSM8409824 GEX-13-689-wk6 GEX-13-689-wk
- GSM8409825 GEX-13-689-wk9 GEX-13-689-wk
- GSM8409826 GEX-13-689-wk12 GEX-13-689-wk
- GSM8409827 GEX-16-2006-wk0 GEX-16-2006-wk
- GSM8409828 GEX-16-2006-wk3 GEX-16-2006-wk
- GSM8409829 GEX-16-2006-wk6 GEX-16-2006-wk
- GSM8409830 GEX-16-2006-wk9 GEX-16-2006-wk
- GSM8409831 GEX-16-2006-wk12 GEX-16-2006-wk
- GSM8409832 GEX-17-3017-wk0 GEX-17-3017-wk
- GSM8409833 GEX-17-3017-wk3 GEX-17-3017-wk
- GSM8409834 GEX-17-3017-wk6 GEX-17-3017-wk
- GSM8409835 GEX-17-3017-wk9 GEX-17-3017-wk
- GSM8409836 GEX-17-3017-wk12 GEX-17-3017-wk
- GSM8409837 GEX-18-3282-wk0 GEX-18-3282-wk
- GSM8409838 GEX-18-3282-wk3 GEX-18-3282-wk
- GSM8409839 GEX-18-3282-wk6 GEX-18-3282-wk
- GSM8409840 GEX-18-3282-wk9 GEX-18-3282-wk
- GSM8409841 GEX-18-3282-wk12 GEX-18-3282-wk
- GSM8409842 TCR-13-689-wk0 TCR-13-689-wk
- GSM8409843 TCR-13-689-wk3 TCR-13-689-wk
- GSM8409844 TCR-13-689-wk6 TCR-13-689-wk
- GSM8409845 TCR-13-689-wk9 TCR-13-689-wk
- GSM8409846 TCR-13-689-wk12 TCR-13-689-wk
- GSM8409847 TCR-16-2006-wk0 TCR-16-2006-wk
- GSM8409848 TCR-16-2006-wk3 TCR-16-2006-wk
- GSM8409849 TCR-16-2006-wk6 TCR-16-2006-wk
- GSM8409850 TCR-16-2006-wk9 TCR-16-2006-wk
- GSM8409851 TCR-16-2006-wk12 TCR-16-2006-wk
- GSM8409852 TCR-17-3017-wk0 TCR-17-3017-wk
- GSM8409853 TCR-17-3017-wk3 TCR-17-3017-wk
- GSM8409854 TCR-17-3017-wk6 TCR-17-3017-wk
- GSM8409855 TCR-17-3017-wk9 TCR-17-3017-wk
- GSM8409856 TCR-17-3017-wk12 TCR-17-3017-wk
- GSM8409857 TCR-18-3282-wk0 TCR-18-3282-wk
- GSM8409858 TCR-18-3282-wk3 TCR-18-3282-wk
- GSM8409859 TCR-18-3282-wk6 TCR-18-3282-wk
- GSM8409860 TCR-18-3282-wk9 TCR-18-3282-wk
- GSM8409861 TCR-18-3282-wk12 TCR-18-3282-wk
- GSE272993 Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8 T cells [dataset 1] 360 samples shares anti-pd-1, cd8, progenitor-exhausted, combination, anti-ctla-4, generates, therapy, include
- GSE295599 Combinatorial delivery of low-dose irradiation and immunotherapy to patients with immune-excluded tumors effectively enhances CD8+ T cell functionality in tumors with homologous recombination repair deficiency [bulk RNA-seq] 29 samples shares cd8, combination, therapy
- GSE295600 Combinatorial delivery of low-dose irradiation and immunotherapy to patients with immune-excluded tumors effectively enhances CD8+ T cell functionality in tumors with homologous recombination repair deficiency [scRNA-seq] 18 samples shares cd8, combination, therapy
- GSE235863 T cell populations correlate with response and resistance to anti-PD-1 plus lenvatinib combination therapy in hepatocellular carcinoma 69 samples shares anti-pd-1, combination, therapy
- GSE286827 4-1BB+ Tregs and inhibitory progenitor exhausted T cells confer resistance to anti-PD-L1 and anti-CTLA-4 combination therapy 87 samples shares combination, anti-ctla-4, therapy
- GSE235093 Pre-existing skin-resident CD8 and γδ T cell circuits mediate immune response in Merkel cell carcinoma and Predict immunotherapy efficacy 333 samples shares cd8, therapy
- GSE235090 Pre-existing skin-resident CD8 and γδ T cell circuits mediate immune response in Merkel cell carcinoma and Predict immunotherapy efficacy [scRNA_tissue] 192 samples shares cd8, therapy
- GSE235092 Pre-existing skin-resident CD8 and γδ T cell circuits mediate immune response in Merkel cell carcinoma and Predict immunotherapy efficacy [bulkRNA-seq] 85 samples shares cd8, therapy
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.